BioSpace News Archive

Tharimmune, Inc. announced that management will be participating in two investor conferences in May.

Neogen® Corporation announced the launch of the new Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium.

ARS Pharmaceuticals, Inc. announced that it has submitted its Day 180 response to the Committee for Medicinal Products for Human Use of the European Medicines Agency for its Marketing Authorization Application for neffy®, an investigational new drug to be indicated for the treatment of Type I allergic reactions including anaphylaxis.

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO) today announced the initiation of a Phase 2 investigator-sponsored trial (“IST”) of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA® (pembrolizumab) in patients with previously untreated and early-stage locally advanced, resectable, human papillomavirus-mediated oropharyngeal cancer (“HPVOC”).

Kamari Pharma announced the appointment of John Doux, MD, MBA, to the company’s Board of Directors.

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS

Olympus will highlight a diverse urology portfolio that can help physicians treat bladder cancer, urinary stones and enlarged prostate during this year’s American Urological Association annual meeting May 3-6 in San Antonio.

According to recent study by nova one advisor, the U.S. tissue diagnostics market size was exhibited at USD 2.46 billion in 2023 and is projected to hit around USD 3.61 billion by 2033, growing at a CAGR of 3.92 % during the forecast period 2024 to 2033.

AB Science SA announced that it has postponed the publication of its 2023 annual financial report, initially scheduled for 30 April 2024, to give the auditors time to complete their audit work.

The Stowers Institute for Medical Research announces the appointment of Kamena Kostova, Ph.D., as its newest Principal Investigator.